Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis

Joint Bone Spine

Volumn 74, Issue 5, 2007, Pages 500-503

  García Carrasco, Mario ^a,b   Fuentes Alexandro, Salvador ^a   Escárcega, Ricardo O ^d   Rojas Rodriguez, Jorge ^b   Escobar, Luis E ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^c Hospital Guadalupe   (Mexico)

^d NONE

Author keywords

Systemic juvenile arthritis; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYTOKINE; ETANERCEPT; IMMUNOMODULATING AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; THALIDOMIDE;

ARTICLE; CASE REPORT; CHILD; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; REMISSION; TREATMENT OUTCOME;

AGE OF ONSET; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 35348974044     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2006.12.004     Document Type: Article

References (18)

1. Lomater C., Gerloni V., Gattinara M., Mazzotti J., Cimaz R., and Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J Rheumatol 27 (2000) 491-496
2. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis. second revision, Edmonton. J Rheumatol 2004 31 (2001) 390-392
3. Adams A., and Lehman T.J.A. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Curr Opin Rheumatol 17 (2005) 612-616
4. Spahn J.D., and Kamada A.K. Special considerations in the use of glucocorticoids in children. Pediatr Rev 16 (1995) 266-272
5. Dredge K., Marriot J.B., and Dalgiesh A.G. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol 22 (2002) 425-437
6. Wu J.J., Huang D.B., Pang K.R., Hsu S., and Tyring S.K. Thalidomide: dermatological indications, mechanisms of action and side-effects. Br J Dermatol 153 (2005) 254-273
7. Wallace C.A., Ruperto N., Giannini E., Childhood Arthritis and Rheumatology Research Alliance, and Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 31 (2004) 2290-2294
8. Muller K., Herner E.B., Stagg A., Bendtzen K., and Woo P. Inflammatory cytokines and cytokine antagonists in whole blood cultures of patients with systemic juvenile chronic arthritis. Br J Rheumatol 37 (1998) 562-569
9. Murray K.J., Grom A.A., Thompson S.D., Lieuwen D., Passo M.H., and Glass D.N. Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol 25 (1998) 1388-1398
10. Date Y., Seki N., Kamizono S., Higuchi T., Hirata T., Miyata K., et al. Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5′-flanking region of the TNF alpha gene and HLA genes. Arthritis Rheum 42 (1999) 2577-2582
11. de Benedetti F., Massa M., Robbioni P., Ravelli A., Burgio G.R., and Martini A. Correlation of interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 34 (1991) 1158-1163
12. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102 (1998) 1369-1376
13. De Benedetti F., Pignatti P., Bernasconi S., Gerloni V., Matsushima K., Caporali R., et al. Interleukin 8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis: relation to onset types, disease activity, and synovial fluid leukocytes. J Rheumatol 26 (1999) 425-431
14. De Benedetti F., Meazza C., Vivarelli M., Rossi F., Pistorio A., Lamb R., et al., British Paediatric Rheumatology Study Group. Functional and prognostic relevance of the-173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 48 (2003) 1398-1407
15. Faver I.R., Guerra S.G., Su W.P., and el-Azhary R. Thalidomide for dermatology: a review of clinical uses and adverse effects. Int J Dermatol 44 (2005) 61-67
16. Lehman T.J., Striegel K.H., and Onel K.B. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr 140 (2002) 125-127
17. Lehman T.J., Schechter S.J., Sundel R.P., Oliveira S.K., Huttenlocher A., and Onel K.B. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: a multi center study. J Pediatr 145 (2004) 856-857
18. Quartier P. When should we use TNF antagonists in children with rheumatic disease?. Joint Bone Spine 74 (2007) 1-3